Skip to search formSkip to main contentSkip to account menu

Pancreatic Ductal Adenocarcinoma

Known as: Ductal Adenocarcinoma of Pancreas, Pancreas Ductal Adenocarcinoma, Pancreatic Infiltrating Duct Carcinoma, NOS 
An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas. It affects males more often than females and the patients are… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Cancer-associated fibroblasts (CAFs) are major players in the progression and drug resistance of pancreatic ductal adenocarcinoma… 
Highly Cited
2015
Highly Cited
2015
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival rate of 4%. A key hallmark of PDAC is… 
Highly Cited
2012
Highly Cited
2012
Pancreatic cancer is a highly lethal malignancy with few effective therapies. We performed exome sequencing and copy number… 
Highly Cited
2011
Highly Cited
2011
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis. Numerous phase… 
Highly Cited
2007
Highly Cited
2007
CONTEXT While global microRNA (miRNA) expression patterns of many embryologic, physiologic, and oncogenic processes have been… 
Review
2006
Review
2006
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median survival… 
Highly Cited
2003
Highly Cited
2003
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions… 
Review
1996
Review
1996
OBJECTIVE The authors reviewed the clinicopathologic characteristics of patients who underwent resection with curative intent for…